Barely Significant
← all excerpts

Encorafenib plus binimetinib versus dabrafenib plus trametinib for the first-line treatment of patients with BRAF<sup>V600E</sup>-mutant metastatic non-small cell lung cancer: a matching-adjusted indirect treatment comparison.

ESMO Open · 2026 · PMC12865620 · PMID 41604820

Europe PMCDOI
1
hedged sentence
0.2100
closest p · 4.2× alpha
0.2100
boldest claim

The sentences

did not reach statistical significanceP = 0.21not close (p > 0.1)
The estimated difference in odds of objective response with E + B compared with D + T did not reach statistical significance at a 95% confidence level in either the matching-adjusted indirect treatment comparison (OR = 1.81; 95% CI 0.71-4.59; P = 0.21) or the unadjusted indirect treatment comparison (OR for ORR = 1.66; 95% CI 0.68-4.07; P = 0.27; Table 2 ).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.